GlassScriptPhysician profile
Natalie Dubchak
NPI 1760638050
$19,047.64
in general payments reported to CMS, 2019-2025
50 companies · $2,635 in 2025
The $2,635 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,463 · 2020: $1,869 · 2021: $3,048 · 2022: $2,761 · 2023: $2,539 · 2024: $2,732 · 2025: $2,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,796 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,795.95 |
| Education | $109.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,402.93 | 2019-2025 | Enbrel, Otezla, Evenity |
| Abbvie INC. | $2,397.37 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,477.95 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $1,391.80 | 2019-2025 | Bimzelx, Cimzia, Rystiggo |
| Pfizer INC. | $1,227.84 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,021.16 | 2019-2024 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $902.47 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $553.80 | 2019-2025 | Taltz, Kisunla, Amyvid |
| Novartis Pharmaceuticals Corporation | $460.87 | 2019-2025 | |
| Genentech USA, INC. | $414.76 | 2019-2025 | Actemra, Ocrevus, Enspryng |
| E.R. Squibb & Sons, L.L.C. | $409.80 | 2019-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $342.11 | 2020-2022 | |
| Radius Health, INC. | $276.46 | 2019-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $253.67 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $236.55 | 2023-2025 | Idacio |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $226.57 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $190.98 | 2021-2025 | Ultomiris, Soliris |
| Celgene Corporation | $173.96 | 2019 | |
| Ferring Pharmaceuticals INC. | $140.96 | 2024-2025 | Euflexxa |
| Depuy Synthes Sales INC. | $127.86 | 2020-2025 | Monovisc, Orthovisc |
| Sobi, INC | $125.02 | 2019-2025 | |
| Cumberland Pharmaceuticals, INC. | $121.70 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $96.44 | 2023-2025 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $92.76 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $91.46 | 2021 | |
| Aurinia Pharma U.S., INC. | $84.98 | 2021-2025 | Lupkynis |
| Eisai INC. | $74.99 | 2023-2024 | |
| Biogen, INC. | $69.53 | 2022-2023 | Tysabri, Vumerity |
| Medexus Pharma, INC. | $66.97 | 2019 | |
| Hikma Pharmaceuticals USA | $61.59 | 2019-2021 | |
| Tg Therapeutics, INC. | $51.21 | 2024-2025 | |
| Argenx US, INC. | $45.39 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Assertio Therapeutics, INC. | $40.95 | 2020 | |
| Daiichi Sankyo INC. | $38.56 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $38.08 | 2021 | |
| Mdd US Operations, LLC | $34.37 | 2024 | Gocovri |
| Sandoz INC. | $32.31 | 2023-2024 | Hyrimoz |
| Csl Behring | $30.46 | 2024 | Hizentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.22 | 2024 | Cyltezo |
| Vanda Pharmaceuticals INC. | $25.31 | 2024 | Ponvory |
| Fidia Pharma USA INC. | $24.06 | 2024 | Hymovis |
| Averitas Pharma INC. | $21.50 | 2025 | Qutenza |
| Neurelis, INC. | $20.60 | 2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $17.31 | 2025 | Austedo Xr |
| Alvogen INC | $15.84 | 2025 | Teriparatide |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.25 | 2025 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $14.35 | 2021 | |
| Almatica Pharma LLC | $13.90 | 2025 | Teriparatide |
| Horizon Therapeutics Plc | $12.34 | 2020 | |
| Avion Pharmaceuticals | $12.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Dubchak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.